 Iradimed NASDAQ: IRMD has recently received a number of price target changes and ratings updates: 432020 Iradimed was downgraded by analysts at ValuEngine from a buy rating to a hold rating. 3312020 Iradimed was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They now have a ... 